ArticleMedicine2016
Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis.
Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Prognostic value of combined baseline FDG PET/CT radiomic parameters in primary mediastinal B-cell lymphoma.Blood advances · 2026Article
- Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study.Blood advances · 2025Article
- Primary Mediastinal B-Cell Lymphoma and [18F]FDG PET/CT: What We Learned and What Is New.Hematology reports · 2025Review
- Article
- Changes in sex-specific incidence of lymphoid neoplasms across the lifespan.Haematologica · 2024Article
- Article
- Major impact of prognosis by age and sex in patients with primary mediastinal large B‑cell lymphoma.Oncology letters · 2024Article
- Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.Blood advances · 2023Article
- Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies.Haematologica · 2023Article
- Sex differences in lymphoma incidence and mortality by subtype: A population-based study.American journal of hematology · 2023Article
- Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.Blood advances · 2021Article
- Antibody Therapies for Large B-Cell Lymphoma.Biologics : targets & therapy · 2021Review
- Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions.Frontiers in oncology · 2021Review
- Hodgkin Reed-Sternberg-Like Cells in Non-Hodgkin Lymphoma.Diagnostics (Basel, Switzerland) · 2020Review
- Pediatric mediastinal lymphoma.Mediastinum (Hong Kong, China) · 2020Review
- Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma.Current hematologic malignancy reports · 2019Review
- Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.British journal of haematology · 2019Review
- MiRNA Dysregulation in Childhood Hematological Cancer.International journal of molecular sciences · 2018Review
- How I treat primary mediastinal B-cell lymphoma.Blood · 2018Review
- Superior vena cava syndrome related to mediastinal lymphoma in late pregnancy: A case report.Case reports in women's health · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to investigate the incidence and clinical outcomes of primary mediastinal large B-cell lymphoma (PMBL).Here we did a retrospective analysis using the surveillance, epidemiology, and end results (SEER) database to analyze the incidences and survival of patients with PMBL diagnosed during 2001-2012 among major ethnic groups.During 2001-2012, a total of 426 PMBL patients were identified, including 336 whites, 46 blacks, and 44 others. The incidence rates of female to male ratios in white, black, and other were 1.4938, 1.1202, and 1.7303 respectively, suggesting that the female-prominent disease occurrence was seen only in whites and others, but not in black population. Compared to white, the other had a worse 5-year overall survival (OS); however, factors including age, race, socioeconomic status, and stage associated with OS showed no significant difference among ethnic groups; thus, biology factors should be explored to explain the racial difference in OS.In conclusion, our findings revealed diversities in demographic features and prognosis among different racial groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.